Didox

Drug Profile

Didox

Alternative Names: N,3,4-trihydroxybenzamide (Didox); NSC 324360; VF 14

Latest Information Update: 29 Mar 2011

Price : $50

At a glance

  • Originator Molecules for Health
  • Class Antineoplastics; Benzamides; Hydroxamic acids; Small molecules
  • Mechanism of Action Ribonucleoside triphosphate reductase inhibitors; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Cytomegalovirus infections; HIV infections; Psoriasis

Most Recent Events

  • 29 Mar 2011 No development reported - Phase-II for Cancer in United Kingdom (IV)
  • 29 Mar 2011 No development reported - Preclinical for Psoriasis in USA (unspecified route)
  • 29 Mar 2011 No development reported - Preclinical for HIV infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top